KRAS and flatulence: Target sequencing of 68 patients with GAS revealed somatic mutations in TP53 (41%), CDKN2A (18%), KRAS (18%), and STK11 (10%), and potentially targetable mutations in ERBB3 (10%), ERBB2 (8%), and BRAF (4%).